Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Trainor

Showing results (81-90 of 104) with videos related to

Pageof 11
Sort By:
Journal of Medicinal Chemistry|February 22, 2020
Discovery and Optimization of Novel Pyrazolopyrimidines as Potent and Orally Bioavailable Allosteric HIV-1 Integrase InhibitorsGuo Li, Nicholas A Meanwell, Mark R Krystal, et al.
The Journal of Pediatrics|May 11, 2020
Hypertension during Diabetic Ketoacidosis in ChildrenAndrew DePiero, Nathan Kuppermann, Kathleen M Brown, et al.
JAMA Network Open|December 4, 2020
Frequency and Risk Factors of Acute Kidney Injury During Diabetic Ketoacidosis in Children and Association With Neurocognitive OutcomesSage R Myers, Nicole S Glaser, Jennifer L Trainor, et al.
Endocrinology, Diabetes & Metabolism|February 15, 2023
Cognitive function following diabetic ketoacidosis in young children with type 1 diabetesSimona Ghetti, Nathan Kuppermann, Arleta Rewers, et al.
ACS Medicinal Chemistry Letters|August 20, 2015
Structure-Based Design of Selective Janus Kinase 2 Imidazo[4,5-d]pyrrolo[2,3-b]pyridine InhibitorsAmy C Hart, Gretchen M Schroeder, Honghe Wan, et al.
Diabetes Care|September 23, 2020
Cognitive Function Following Diabetic Ketoacidosis in Children With New-Onset or Previously Diagnosed Type 1 DiabetesSimona Ghetti, Nathan Kuppermann, Arleta Rewers, et al.
Bioorganic & Medicinal Chemistry Letters|April 9, 2008
Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737), an in vivo active potent VEGFR-2 inhibitorRéjean Ruel, Carl Thibeault, Alexandre L'Heureux, et al.
Bioorganic & Medicinal Chemistry Letters|July 4, 2012
Synthesis and structure-activity relationships of pyrido[3,2-b]pyrazin-3(4H)-ones and pteridin-7(8H)-ones as corticotropin-releasing factor-1 receptor antagonistsCarolyn D Dzierba, Thais M Sielecki, Argyrios G Arvanitis, et al.
Journal of Medicinal Chemistry|April 4, 2007
Dihydropyridopyrazinones and dihydropteridinones as corticotropin-releasing factor-1 receptor antagonists: structure-activity relationships and computational modelingCarolyn D Dzierba, Andrew J Tebben, Richard G Wilde, et al.
Journal of Medicinal Chemistry|November 15, 2002
Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. 3. Structure activity relationships at C3(1,2)Eddy W Yue, C Anne Higley, Susan V DiMeo, et al.
Pageof 11

Showing results (81-90 of 104) with videos related to

Sort By:
Pageof 11
Journal of Medicinal Chemistry|February 22, 2020
Discovery and Optimization of Novel Pyrazolopyrimidines as Potent and Orally Bioavailable Allosteric HIV-1 Integrase InhibitorsGuo Li, Nicholas A Meanwell, Mark R Krystal, et al.
The Journal of Pediatrics|May 11, 2020
Hypertension during Diabetic Ketoacidosis in ChildrenAndrew DePiero, Nathan Kuppermann, Kathleen M Brown, et al.
JAMA Network Open|December 4, 2020
Frequency and Risk Factors of Acute Kidney Injury During Diabetic Ketoacidosis in Children and Association With Neurocognitive OutcomesSage R Myers, Nicole S Glaser, Jennifer L Trainor, et al.
Endocrinology, Diabetes & Metabolism|February 15, 2023
Cognitive function following diabetic ketoacidosis in young children with type 1 diabetesSimona Ghetti, Nathan Kuppermann, Arleta Rewers, et al.
ACS Medicinal Chemistry Letters|August 20, 2015
Structure-Based Design of Selective Janus Kinase 2 Imidazo[4,5-d]pyrrolo[2,3-b]pyridine InhibitorsAmy C Hart, Gretchen M Schroeder, Honghe Wan, et al.
Diabetes Care|September 23, 2020
Cognitive Function Following Diabetic Ketoacidosis in Children With New-Onset or Previously Diagnosed Type 1 DiabetesSimona Ghetti, Nathan Kuppermann, Arleta Rewers, et al.
Bioorganic & Medicinal Chemistry Letters|April 9, 2008
Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737), an in vivo active potent VEGFR-2 inhibitorRéjean Ruel, Carl Thibeault, Alexandre L'Heureux, et al.
Bioorganic & Medicinal Chemistry Letters|July 4, 2012
Synthesis and structure-activity relationships of pyrido[3,2-b]pyrazin-3(4H)-ones and pteridin-7(8H)-ones as corticotropin-releasing factor-1 receptor antagonistsCarolyn D Dzierba, Thais M Sielecki, Argyrios G Arvanitis, et al.
Journal of Medicinal Chemistry|April 4, 2007
Dihydropyridopyrazinones and dihydropteridinones as corticotropin-releasing factor-1 receptor antagonists: structure-activity relationships and computational modelingCarolyn D Dzierba, Andrew J Tebben, Richard G Wilde, et al.
Journal of Medicinal Chemistry|November 15, 2002
Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. 3. Structure activity relationships at C3(1,2)Eddy W Yue, C Anne Higley, Susan V DiMeo, et al.
Pageof 11